Our Pricing

Nevolat vs Wegovy: Which Weight Loss Injection Is Right for You?

When comparing Nevolat vs Wegovy for weight loss, understanding the clinical differences, efficacy data, and UK pricing is essential for making an informed choice. Both medications contain semaglutide, the GLP-1 receptor agonist proven to support significant weight reduction, but they differ in branding, licensing, and availability across UK pharmacies. This guide provides a transparent comparison of Nevolat vs Wegovy, including real-world evidence, dosing schedules, side effect profiles, and upfront costs with no hidden fees.

What Is the Difference Between Nevolat vs Wegovy?

Nevolat vs Wegovy is a common question among patients seeking semaglutide-based weight loss treatment in the UK. Both products contain the same active ingredient—semaglutide 2.4 mg—and work identically by mimicking the GLP-1 hormone to reduce appetite, slow gastric emptying, and improve glycaemic control [1]. The key difference lies in branding and manufacturer: Wegovy is the globally recognised brand name produced by Novo Nordisk, whilst Nevolat is an alternative brand name used in certain markets for the same formulation.

In the UK, Wegovy is the MHRA-licensed and widely prescribed option available through registered pharmacies like Cured Pharmacy. Nevolat, while containing identical semaglutide, is not currently licensed or distributed in the UK under that brand name. Patients searching for Nevolat vs Wegovy in the UK context are typically comparing international branding or exploring whether alternative semaglutide products offer cost advantages. For UK patients, Wegovy remains the gold-standard, licensed option with transparent pricing from £69.00 at Cured Pharmacy, subject to clinical assessment by a UK-registered prescriber [2].

Nevolat vs Wegovy: Clinical Efficacy and Trial Data

When evaluating Nevolat vs Wegovy for weight loss efficacy, the clinical evidence is identical because both contain semaglutide 2.4 mg. The landmark STEP (Semaglutide Treatment Effect in People with obesity) trials demonstrated that semaglutide 2.4 mg led to an average weight loss of 15-17% of initial body weight over 68 weeks, compared to 2.4% with placebo [3]. Participants also experienced improvements in waist circumference, blood pressure, and HbA1c levels, reinforcing semaglutide's role beyond weight reduction.

Since Nevolat vs Wegovy both deliver the same active pharmaceutical ingredient at the same dose, patients can expect equivalent clinical outcomes. The STEP 1 trial specifically showed that 86.4% of participants on semaglutide 2.4 mg achieved at least 5% weight loss, and 69.1% achieved at least 10% weight loss [3]. For UK patients, Wegovy is the licensed, evidence-backed option available through Cured Pharmacy's clinical pathway, ensuring access to genuine medication with full regulatory oversight.

Real-World Evidence Supporting Semaglutide

Beyond controlled trials, real-world data from UK prescribing cohorts confirm that semaglutide 2.4 mg maintains its efficacy in routine clinical practice. Observational studies show sustained weight loss over 12-18 months, with patients reporting improved quality of life and reduced cardiovascular risk markers [4]. Whether branded as Nevolat vs Wegovy, the pharmacological action remains consistent, making Wegovy the trusted, UK-licensed choice for patients seeking medically supervised weight management.

Nevolat vs Wegovy: Side Effects and Safety Profile

The side effect profile for Nevolat vs Wegovy is identical, as both are formulations of semaglutide 2.4 mg. The most commonly reported adverse effects include nausea (44% of participants in STEP trials), diarrhoea (30%), vomiting (24%), and constipation (24%), typically mild to moderate and diminishing over the first 8-12 weeks [1]. These gastrointestinal symptoms reflect semaglutide's mechanism of slowing gastric emptying and are managed by gradual dose escalation.

Serious adverse events are rare but include pancreatitis, gallbladder disease, and hypoglycaemia (particularly in patients on concurrent diabetes medications). The MHRA and Novo Nordisk provide clear prescribing guidance to minimise these risks, including contraindications for patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 [2]. When comparing Nevolat vs Wegovy, UK patients benefit from Wegovy's full regulatory approval, comprehensive patient information leaflets, and clinical oversight through pharmacies like Cured Pharmacy, where every prescription is reviewed by superintendent pharmacist Tarun Kumar (GPhC 2233073).

Nevolat vs Wegovy: UK Pricing and Transparency

Price is a central consideration in the Nevolat vs Wegovy debate, particularly for patients funding treatment privately. In the UK, Wegovy is available from Cured Pharmacy at a transparent starting price of £69.00 per dose, with no hidden consultation fees or surprise charges. Patients also receive £20 off their first order using code Weightlossnew, making the initial cost £69.00. This upfront pricing model ensures patients know exactly what they will pay before completing their clinical assessment.

Nevolat, while theoretically identical in formulation, is not currently available through UK-licensed pharmacies under that brand name. Patients seeking Nevolat vs Wegovy comparisons should be cautious of unlicensed imports or international suppliers, which may lack MHRA oversight, proper storage conditions, or valid prescribing pathways. Cured Pharmacy guarantees 100% genuine, UK-licensed Wegovy, dispensed following consultation with a UK-registered prescriber, and delivered in discreet packaging with next-day options available.

Why Transparent Pricing Matters

Many UK patients report frustration with hidden fees—consultation charges, delivery costs, or inflated 'membership' models. Cured Pharmacy's pricing for Wegovy is all-inclusive: the advertised £69.00 covers the medication, free clinical consultation (completed in under 3 minutes), and standard delivery. This transparency is critical when comparing Nevolat vs Wegovy or any weight loss treatment, ensuring patients can budget accurately without unexpected costs.

Nevolat vs Wegovy: Dosing Schedule and Administration

The dosing regimen for Nevolat vs Wegovy is identical, following a gradual escalation protocol to minimise gastrointestinal side effects. Patients begin with 0.25 mg once weekly for 4 weeks, then increase to 0.5 mg, 1 mg, 1.7 mg, and finally the maintenance dose of 2.4 mg over 16-20 weeks [1]. Each dose is administered via subcutaneous injection using a pre-filled pen, designed for self-administration in the abdomen, thigh, or upper arm.

Wegovy pens available through Cured Pharmacy are user-friendly, with clear dosing windows and safety features to prevent accidental needle stick injuries. The injection is once weekly, on the same day each week, offering convenience compared to daily medications. When weighing Nevolat vs Wegovy, UK patients benefit from Wegovy's established supply chain, comprehensive patient support materials, and regulatory-compliant packaging, all backed by Cured Pharmacy's GPhC-registered dispensing service (9012511).

Nevolat vs Wegovy: Which Should You Choose in the UK?

For UK patients, the choice between Nevolat vs Wegovy is straightforward: Wegovy is the licensed, evidence-based, and widely available option through registered pharmacies like Cured Pharmacy. Whilst Nevolat may be marketed internationally under alternative branding, it is not currently licensed by the MHRA for use in the UK, meaning patients cannot access it through legitimate UK prescribing channels. Choosing Wegovy ensures full regulatory protection, genuine medication sourced from licensed wholesalers, and clinical oversight by UK-registered healthcare professionals.

Wegovy's proven efficacy—demonstrated across multiple STEP trials with over 4,500 participants—combined with Cured Pharmacy's transparent pricing (from £69.00, with £20 off first orders using code Weightlossnew) makes it the optimal choice for medically supervised weight loss in the UK. Every Wegovy prescription requires an online clinical assessment by a UK prescriber, ensuring suitability, safety, and compliance with NICE and MHRA guidelines [2]. Patients receive genuine medication, discreet delivery, and ongoing support from a team led by superintendent pharmacist Tarun Kumar.

How to Start Wegovy with Cured Pharmacy

Starting Wegovy is simple: complete a free online consultation (under 3 minutes), receive prescriber review within hours, and have your medication dispatched the same day if approved. Cured Pharmacy's streamlined process eliminates the need for GP appointments or long waiting times, whilst maintaining full clinical rigour. When comparing Nevolat vs Wegovy, the clear winner for UK patients is Wegovy, delivered with transparency, expertise, and the lowest prices guaranteed.

Scientific References

1. Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., ... & Kushner, R. F. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989-1002. [accessed 15 August 2026]
2. Medicines and Healthcare products Regulatory Agency. (2023). Wegovy 2.4 mg solution for injection in pre-filled pen: Summary of Product Characteristics. GOV.UK. [accessed 15 August 2026]
3. Garvey, W. T., Batterham, R. L., Bhatta, M., Buscemi, S., Christensen, L. N., Frias, J. P., ... & Wharton, S. (2022). Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine, 28(10), 2083-2091. [accessed 15 August 2026]
4. Rubino, D. M., Greenway, F. L., Khalid, U., O'Neil, P. M., Rosenstock, J., Sørrig, R., ... & Wilding, J. P. H. (2021). Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes. JAMA, 327(2), 138-150. [accessed 15 August 2026]
5. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 15 August 2026.
6. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 15 August 2026.
7. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 15 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.